iRadimed (IRMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

iRadimed

NasdaqGM•Healthcare•Medical Devices

$76.68-9.06(-0.11%)Market closed

Market Cap

$1.02B

P/E

42.3x

P/S

11.4x

P/B

9.5x

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

How this company scores

ExcellentMetricSide Score: 83/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability25/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality23/25

Strengths

Rising free cash flowStrong marginsHigh ROEInterest easily covered

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 42.3x5y range 33.5x – 65.8x

Currently near its 20-quarter median.

P/S · 11.4x5y range 8.8x – 14.9x

Currently near its 20-quarter median.

P/B · 9.5x5y range 7.4x – 13.2x

Price & Volume

Market Cap $1.02B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $89.34M
Q. Revenue: $24.20M
TTM EBITDA: $31.11M
TTM Op. Income: $28.86M
Q. Op. Income: $8.14M
TTM Net Income: $23.98M
Q. Net Income: $6.51M
EPS: $0.51
Shares Out.: $12.79M

$89.34M in TTM revenue grew 11.0% YoY, reaching $24.20M last quarter. TTM EBITDA of $31.11M and TTM operating income of $28.86M show growth is flowing through to the bottom line. TTM net income of $23.98M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 76.3%
EBITDA Margin: 35.3%
Op. Margin: 33.6%
Net Margin: 26.9%

Op. margin of 33.6% is up 1.4% YoY — cost efficiency is improving. Net margin at 26.9% and gross margin of 76.3% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 4% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 42.3x
P/S Ratio: 11.4x
P/B Ratio: 9.5x

At 42.3x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 11.4x and P/B of 9.5x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 1% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $121.07M
Cash: $63.29M
Long-Term Debt: N/A
Book Value: $106.45M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $7.00M
TTM Free Cash Flow: $26.14M
FCF Margin: 29.3%
FCF / Net Income: 1.1

TTM FCF of $26.14M on $7.00M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.